A potential target of GXYLT2 affecting the prognosis of gastric cancer by enhancing the EMT process: A clinical retrospective study

Zhao,Yunxia; Li,Li; Cai,Zhaogen

doi:10.3892/ol.2024.14767

A potential target of GXYLT2 affecting the prognosis of gastric cancer by enhancing the EMT process: A clinical retrospective study

Authors:
- Yunxia Zhao
- Li Li
- Zhaogen Cai
View Affiliations

Affiliations: Department of Pathophysiology, Bengbu Medical University, Bengbu, Anhui 233030, P.R. China, Department of Pathology, The First Hospital of Bengbu Medical University, Bengbu, Anhui 233030, P.R. China
Published online on: October 23, 2024 https://doi.org/10.3892/ol.2024.14767
Article Number: 22
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate glucoside xylosyltransferase 2 (GXYLT2) as a potential prognostic marker for gastric cancer (GC). The expression levels of GXYLT2, Notch1, E‑cadherin and vimentin in GC and adjacent tissues were detected by Elivision™️ Plus immunohistochemistry. The relationship between GXYLT2, Notch1, E‑cadherin and vimentin, and clinicopathological parameters was also analyzed. Univariate and multivariate Cox regression analyses were conducted to evaluate the effect of GXYLT2 on survival. The results revealed that GC tissues exhibited a marked increase in GXYLT2, Notch1 and vimentin, and a marked reduction in E‑cadherin. The expression of GXYLT2 was related to the differentiation degree of GC and the pathological tumor‑node‑metastasis (pTNM) stage; the expression of Notch1 was related to the vascular and nerve infiltration of GC; and E‑cadherin and vimentin expression were related to patient age, tumor size, tumor differentiation degree, depth of infiltration, lymph node metastasis and pTNM stage. Positive associations existed between GXYLT2 and Notch1 expression, GXYLT2 and vimentin expression, and Notch1 and vimentin expression. Furthermore, the Kaplan‑Meier analysis showed that survival and prognosis were associated with factors such as GXYLT2 protein levels, pTNM stage, tumor dimensions, depth of infiltration and lymph node metastasis. Through Cox regression analysis, GXYLT2 was identified as an independent predictor for GC. In conclusion, GXYLT2 may be related to the pathogenesis of GC, and its abnormal expression could be associated with epithelial‑mesenchymal transition. Consequently, GXYLT2 may be considered a promising prognostic marker in the context of GC.

View Figures

View References

1	Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024. View Article : Google Scholar
2	Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ, Estève J, et al: Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 391:1023–1075. 2018. View Article : Google Scholar
3	Bray F, Laversanne M, Weiderpass E and Soerjomataram I: The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 127:3029–3030. 2021. View Article : Google Scholar
4	Siegel RL, Miller KD, Wagle NS and Jemal A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48. 2023. View Article : Google Scholar
5	Miao ZF, Chen H, WangZ N, Jia-Fu JI, Liang H, Xu HM and Wang J: Progress and remaining challenges in comprehensive gastric cancer treatment. Holistic Integrative Oncology. 1:2731–4529. 2022. View Article : Google Scholar
6	Lairson LL, Henrissat B, Davies GJ and Withers SG: Glycosyltransferases: Structures, functions, and mechanisms. Annu Rev Biochem. 77:521–555. 2008. View Article : Google Scholar
7	Lee TV, Sethi MK, Leonardi J, Rana NA, Buettner FF, Haltiwanger RS, Bakker H and Jafar-Nejad H: Negative regulation of notch signaling by xylose. PLoS Genet. 9:e10035472013. View Article : Google Scholar
8	Sethi MK, Buettner FFR, Krylov VB, Takeuchi H, Nifantiev NE, Haltiwanger RS, Gerardy-Schahn R and Bakker H: Identification of glycosyltransferase 8 family members as xylosyltransferases acting on O-glucosylated notch epidermal growth factor repeats. J Biol Chem. 285:1582–1586. 2010. View Article : Google Scholar
9	Shi Q, Xue C, Zeng Y, Yuan X, Chu Q, Jiang S, Wang J, Zhang Y, Zhu D and Li L: Notch signaling pathway in cancer: From mechanistic insights to targeted therapies. Signal Transduct Target Ther. 27:1282024. View Article : Google Scholar
10	Bakker H and Gerardy-Schahn R: A sweet development in Notch regulation. J Biol Chem. 292:15974–15975. 2017. View Article : Google Scholar
11	Wharton KA, Johansen KM, Xu T and Artavanis-Tsakonas S: Nucleotide sequence from the neurogenic locus notch implies a gene product that shares homology with proteins containing EGF-like repeats. Cell. 43:567–581. 1985. View Article : Google Scholar
12	Blavier L, Lazaryev A, Shi X-H, Dorey FJ, Shackleford GM and DeClerck YA: Stromelysin-1 (MMP-3) is a target and a regulator of Wnt1-induced epithelial-mesenchymal transition (EMT). Cancer Biol Ther. 10:198–208. 2010. View Article : Google Scholar
13	Chen T, You Y, Jiang H and Wang ZZ: Epithelial-mesenchymal transition (EMT): A biological process in the development, stem cell differentiation, and tumorigenesis. J Cell Physiol. 232:3261–3272. 2017. View Article : Google Scholar
14	Kim DH, Xing T, Yang Z, Dudek R, Lu Q and Chen YH: Epithelial mesenchymal transition in embryonic development, tissue repair and cancer: A comprehensive overview. J Clin Med. 7:12017. View Article : Google Scholar
15	Amack JD: Cellular dynamics of EMT: Lessons from live in vivo imaging of embryonic development. Cell Commun Signal. 19:792021. View Article : Google Scholar
16	Urata Y, Saiki W, Tsukamoto Y, Sago H, Hibi H, Okajima T and Takeuchi H: Xylosyl Extension of O-Glucose glycans on the extracellular domain of NOTCH1 and NOTCH2 regulates notch cell surface trafficking. Cells. 9:12202020. View Article : Google Scholar
17	Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and Winchester DP: The eighth edition AJCC Cancer Staging Manual: Continuing to build a bridge from a Population-based to a more ‘personalized’ approach to cancer staging. CA Cancer J Clin. 67:93–99. 2017. View Article : Google Scholar
18	Weiser TG, Haynes AB, Molina G, Lipsitz SR, Esquivel MM, Uribe-Leitz T, Fu R, Azad T, Chao TE, Berry WR and Gawande AA: Size and distribution of the global volume of surgery in 2012. Bull World Health Organ. 94:201–209F. 2016. View Article : Google Scholar
19	Cisło M, Filip AA, Arnold Offerhaus GJ, Ciseł B, Rawicz-Pruszyński K, Skierucha M and Polkowski WP: Distinct molecular subtypes of gastric cancer: From Laurén to molecular pathology. Oncotarget. 9:19427–19442. 2018. View Article : Google Scholar
20	Hancock CN, Kent L and McClure BA: The stylar 120 kDa glycoprotein is required for S-specific pollen rejection in Nicotiana. Plant J. 43:716–723. 2005. View Article : Google Scholar
21	Josè-Estanyol M and Puigdomènech P: Plant cell wall glycoproteins and their genes. Plant Physiol Biochem. 38:97–108. 2000. View Article : Google Scholar
22	Pearce G, Siems WF, Bhattacharya R, Chen YC and Ryan CA: Three hydroxyproline-rich glycopeptides derived from a single petunia polyprotein precursor activate defensin I, a pathogen defense response gene. J Biol Chem. 282:17777–17784. 2007. View Article : Google Scholar
23	Tan Z, Lu W, Li X, Yang G, Guo J, Yu H, Li Z and Guan F: Altered N-Glycan expression profile in epithelial-to-mesenchymal transition of NMuMG cells revealed by an integrated strategy using mass spectrometry and glycogene and lectin microarray analysis. J Proteome Res. 13:2783–2795. 2014. View Article : Google Scholar
24	Fuster MM and Esko JD: The sweet and sour of cancer: Glycans as novel therapeutic targets. Nat Rev Cancer. 5:526–542. 2005. View Article : Google Scholar
25	Munkley J and Elliott DJ: Hallmarks of glycosylation in cancer. Oncotarget. 7:35478–35489. 2016. View Article : Google Scholar
26	Pinho SS and Reis CA: Glycosylation in cancer: Mechanisms and clinical implications. Nat Rev Cancer. 15:540–555. 2015. View Article : Google Scholar
27	Zhao Y, Hu S, Zhang J, Cai Z, Wang S, Liu M, Dai J and Gao Y: Glucoside xylosyltransferase 2 as a diagnostic and prognostic marker in gastric cancer via comprehensive analysis. Bioengineered. 12:5641–5654. 2021. View Article : Google Scholar
28	Wu Y and Liao Q: MicroRNA-204-5p hampers the malignant progression of clear cell renal cell carcinoma through GXYLT2 downregulation. Kidney Blood Press Res. 47:654–663. 2022. View Article : Google Scholar
29	Zhou ZH, Wang QL, Mao LH, Li XQ, Liu P, Song JW, Liu X, Xu F, Lei J and He S: Chromatin accessibility changes are associated with enhanced growth and liver metastasis capacity of Acid-adapted colorectal cancer cells. Cell Cycle. 18:511–522. 2019. View Article : Google Scholar
30	Rana NA, Nita-Lazar A, Takeuchi H, Kakuda S, Luther KB and Haltiwanger RS: O-glucose trisaccharide is present at high but variable stoichiometry at multiple sites on mouse Notch1. J Biol Chem. 286:31623–31637. 2011. View Article : Google Scholar
31	Dongre A and Weinberg RA: New insights into the mechanisms of Epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 20:69–84. 2019. View Article : Google Scholar
32	Cui Q, Xing J, Gu Y, Nan X, Ma W, Chen Y and Zhao H: GXYLT2 accelerates cell growth and migration by regulating the Notch pathway in human cancer cells. Exp Cell Res. 376:1–10. 2019. View Article : Google Scholar
33	Song YB, Bao WG, Liu DH, Wei LQ, Yang ST, Miao XJ, Lin CY, Li HJ, Lan D and He HM: Pan-cancer analysis of the prognostic significance and oncogenic role of GXYLT2. Medicine (Baltimore). 102:e356642023. View Article : Google Scholar
34	McNamara MG, Jacobs T, Lamarca A, Hubner RA, Valle JW and Amir E: Impact of high tumor mutational burden in solid tumors and challenges for biomarker application. Cancer Treat Rev. 89:1020842020. View Article : Google Scholar
35	Palmeri M, Mehnert J, Silk AW, Jabbour SK, Ganesan S, Popli P, Riedlinger G, Stephenson R, de Meritens AB, Leiser A, et al: Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers. ESMO Open. 7:1003362022. View Article : Google Scholar
36	Picard E, Verschoor CP, Ma GW and Pawelec G: Relationships between immune landscapes, genetic subtypes and responses to immunotherapy in colorectal cancer. Front Immunol. 11:3692020. View Article : Google Scholar
37	World Medical Association: World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. Nov. 310:2191–2194. 2013.